News Headlines Article

Healthcare Reform’s Impact on Pharma Will Be Larger than Expected
Business Wire

Oliver Wyman has released a report that estimates the post-2016 U.S. pharmaceutical industry revenue impact of the Affordable Care Act (ACA) to be 20 percent, which is in dramatic contrast to the 3 percent estimates that were widely circulated when the ACA was signed into law. The report is online at

The authors of the report, Oliver Wyman Life Sciences Partners Jerry Cacciotti and Mark Mozeson, cite five transformational forces of the ACA that will impact the healthcare system and directly impact pharma.